Prosecution Insights
Prosecution Insights
12 pending office actions • 7 clients • 11 examiners • 10 art units • 0 of 12 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §103 only | 5 (42%) |
| §112 only | 2 (17%) |
| No statute on record | 4 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 2 | 68.5% | +32.6% |
| SHIAO, REI TSANG | 1 | 80.0% | -34.5% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 57.4% | +45.0% |
| BROWE, DAVID | 1 | 25.8% | +28.7% |
| CABRAL, ROBERT S | 1 | 62.3% | +32.6% |
| KOSTURKO, GEORGE W | 1 | 54.2% | +49.1% |
| FISCHER, JOSEPH | 1 | 43.2% | +45.2% |
| SCHLOOP, ALLISON ELIZABETH | 1 | 61.8% | +56.5% |
| SWITZER, JULIET CAROLINE | 1 | 41.9% | +54.1% |
| REGLAS, GILLIAN CHELSEA | 1 | 27.5% | +55.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270361 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | BROWE, DAVID | 26d |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | REGLAS, GILLIAN CHELSEA | 27d |
| 17590986 | METHODS AND COMPOSITIONS FOR DETECTING ESOPHAGEAL NEOPLASIAS AND/OR METAPLASIAS IN THE ESOPHAGUS | SWITZER, JULIET CAROLINE | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270001 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | KOSTURKO, GEORGE W | 99d overdue |
| 18280774 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | RZECZYCKI, PHILLIP MATTHEW | 18d overdue |
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | CABRAL, ROBERT S | 12d |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | MIKNIS, ZACHARY J | 21d |
| 18270361 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | BROWE, DAVID | 26d |
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | FISCHER, JOSEPH | 26d |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | REGLAS, GILLIAN CHELSEA | 27d |
| 17590986 | METHODS AND COMPOSITIONS FOR DETECTING ESOPHAGEAL NEOPLASIAS AND/OR METAPLASIAS IN THE ESOPHAGUS | SWITZER, JULIET CAROLINE | 56d |
| Client (Assignee) | Pending OAs |
|---|---|
| Acceleron Pharma | 3 |
| Disc Medicine | 2 |
| Transcode Therapeutics, Inc. | 2 |
| Encoded Therapeutics | 2 |
| Neurogastrx, Inc. | 1 |
| Vizgen, Inc. | 1 |
| Case Western Reserve University | 1 |
| Art Unit | Apps |
|---|---|
| 1658 | 3 |
| 1691 | 1 |
| 1625 | 1 |
| 1617 | 1 |
| 1614 | 1 |
| 1621 | 1 |
| 1683 | 1 |
| 1682 | 1 |
| 1632 | 1 |
| 1635 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18954145 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Acceleron Pharma, Inc. | MIKNIS, ZACHARY J | 1658 | §103 | Non-Final OA | 77d | Pending | Nov 20, 2024 |
| 18280837 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | Disc Medicine, Inc. | SHIAO, REI TSANG | 1691 | Other | Non-Final OA | 46d overdue | Pending | Sep 07, 2023 |
| 18280774 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | Disc Medicine, Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Non-Final OA | 18d overdue | Pending | Sep 07, 2023 |
| 18270361 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | Transcode Therapeutics, Inc. | BROWE, DAVID | 1617 | §103 | Non-Final OA | 26d | Pending | Jun 29, 2023 |
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | Transcode Therapeutics, Inc. | CABRAL, ROBERT S | 1614 | Other | Non-Final OA | 12d | Pending | Jun 28, 2023 |
| 18270001 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | Neurogastrx, Inc. | KOSTURKO, GEORGE W | 1621 | Other | Non-Final OA | 99d overdue | Pending | Jun 28, 2023 |
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | Acceleron Pharma, Inc. | FISCHER, JOSEPH | 1658 | Other | Non-Final OA | 26d | Pending | May 04, 2023 |
| 18111070 | METHODS OF ANCHORING FRAGMENTED NUCLEIC ACID TARGETS IN A POLYMER MATRIX FOR IMAGING | Vizgen, Inc. | SCHLOOP, ALLISON ELIZABETH | 1683 | §103 | Final Rejection | 71d | Pending | Feb 17, 2023 |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Acceleron Pharma, Inc. | MIKNIS, ZACHARY J | 1658 | §112 | Final Rejection | 21d | Pending | Dec 19, 2022 |
| 17590986 | METHODS AND COMPOSITIONS FOR DETECTING ESOPHAGEAL NEOPLASIAS AND/OR METAPLASIAS IN THE ESOPHAGUS | Case Western Reserve University | SWITZER, JULIET CAROLINE | 1682 | §101 | Non-Final OA | 56d | Pending | Feb 02, 2022 |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | Encoded Therapeutics, Inc. | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Non-Final OA | 27d | Pending | Oct 11, 2021 |
| 17442057 | MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS | Encoded Therapeutics, Inc. | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 60d overdue | Pending | Sep 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial